2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Conditions
Sarcoma
1573
Glioblastoma
512
Gliosarcoma
485
Osteosarcoma
459
Brain Neoplasms
344
Gastrointestinal Stromal Tumors
326
Central Nervous System Neoplasms
296
Neoplasms
291
Dendritic Cell Sarcoma, Interdigitating
286
Astrocytoma
275
Lymphoma
260
Bone Neoplasms
245
Sarcoma, Ewing
238
Breast Neoplasms
238
Glioma
237
Neuroblastoma
230
Rhabdomyosarcoma
227
Melanoma
225
Precursor Cell Lymphoblastic Leukemia-Lymphoma
218
Recurrence
216
Lymphoma, Non-Hodgkin
216
Burkitt Lymphoma
213
Oligodendroglioma
203
Ovarian Neoplasms
202
Lymphoma, Large B-Cell, Diffuse
187
Neoplasm Metastasis
186
Lymphoma, Follicular
172
Leukemia
164
Leukemia, Lymphocytic, Chronic, B-Cell
158
Hodgkin Disease
158
Interventions
mifamurtide
1
Temozolomide
1
Irinotecan
1
FANG vaccine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms, Bone Tissue
×
Sarcoma
×
Clear all
NCT03643133
2026-05-19
SARCOME13
UNICANCER
Phase 2
Active not recruiting
60 enrolled
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts